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Abstract 
Advances in surgical and medical treatments for ovarian cancer have improved prognoses. Platinum drugs in particu‑
lar are pivotal for the medical treatment of ovarian cancer. However, previous studies have revealed that some histo‑
logical subtypes, such as clear cell carcinoma, are resistant to medical treatment, including that with platinum drugs. 
Consequently, the clinical prognosis of advanced clear cell carcinoma is remarkably inferior, primarily because of its 
chemoresistant behavior. The prevalence of clear cell carcinoma is approximately 5 % in the West, but in Japan, its 
prevalence is particularly high, at approximately 25 %. Current medical treatments for advanced clear cell carcinoma 
are difficult to administer, and they have poor efficacy, warranting the development of novel target‑based therapies. 
In this review, we describe medical treatments for clear cell carcinoma and discuss future prospects for therapy. In 
particular, we focus on the mechanism of platinum resistance in clear cell carcinoma, including the role of annexin A4, 
one of the most investigated factors of platinum resistance, as well as the mutant genes and overexpressed proteins 
such as VEGF, PI3K/AKT/mTOR signaling pathway, ARID1A, hepatocyte nuclear factor‑1β, ZNF217. We also review tar‑
geted molecular therapeutics for epithelial ovarian cancer and discuss their role in clear cell carcinoma treatment. We 
review the drugs targeting angiogenesis (bevacizumab, sorafenib, and pazopanib), growth factors (gefitinib, erlotinib, 
lapatinib, trastuzumab, and AMG479), and signaling pathways (temsirolimus, dasatinib, and imatinib), and other drugs 
(oregovomab, volociximab, and iniparib). This current review summarizes and discusses the clinical significance of 
these factors in ovarian clear cell carcinoma as well as their potential mechanisms of action. It may provide new inte‑
grative understanding for future studies on their exact role in ovarian clear cell carcinoma.
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Background
Ovarian cancer has the highest mortality among gyneco-
logical cancers and is associated with 4.2 % of all cancer-
related deaths in women [1]. The four major histological 
subtypes include serous adenocarcinoma (SAC), clear 
cell carcinoma (CCC), endometrioid adenocarcinoma, 
and mucinous adenocarcinoma. Although the underlying 
reason remains unknown, CCC prevalence varies with 
race, with an estimated prevalence of 1–12 % in Europe 
and North America [2] and 15–25 % in Japan. Thus, CCC 
is the second most common histological subtype of epi-
thelial ovarian cancer (EOC) in Japan [2, 3]. Over the past 
decade, advances in surgical and chemotherapeutic man-
agement have improved progression-free survival (PFS) 
and overall survival (OS) rates.
Platinum and taxane agents are typically included in 
standard intravenous regimens administered to women 
requiring first-line chemotherapy for ovarian cancer [4], 
and high response rates (60–80 %) have been shown with 
them. Although these chemotherapies have improved 
PFS and OS in ovarian cancer, some histological sub-
types have shown low response rates. Moreover, stand-
ard chemotherapy using paclitaxel and carboplatin has 
exhibited an approximately 70  % response rate in the 
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treatment of SAC, the most common ovarian carcinoma 
subtype, but only 18–56 % for CCC [3, 5, 6].
CCC tumors tend to present at earlier stages, with 
47–81 % diagnosed at stage I or II, and showing a simi-
lar prognosis to SACs [7]. However, advanced CCC (i.e., 
FIGO stage III or IV) has a poorer prognosis, and avail-
able treatments are less effective owing to its resistance 
toward chemotherapeutic agents. Accordingly, in com-
parison with advanced SAC, the clinical prognosis for 
advanced CCC is remarkably inferior, primarily because 
of its chemoresistant behavior [8–10].
As an alternative to platinum drugs, irinotecan has 
been shown to be a promising candidate for the treat-
ment of CCC in retrospective studies [11, 12] and a 
randomized phase II trial [13]. However, the combina-
tion therapy of irinotecan plus cisplatin (CPT-P) failed 
to show efficacy. A recent randomized phase III trial of 
paclitaxel plus carboplatin (TC) therapy versus irinote-
can plus cisplatin (CPT-P) was conducted by the Japa-
nese Gynecologic Oncology Group (JGOG 3017). This 
trial was the first CCC-specific international clinical trial. 
With a 44.3-month median follow-up, the 2-year PFS was 
73.0 % in the CPT-P arm and 77.6 % in the TC arm. The 
2-year OS was 85.5 % in the CPT-P arm and 87.4 % in the 
TC arm. That is, there were no significant changes in PFS 
and OS at 2 years between the two groups.
Based on these findings, CCC is considered a highly 
malignant and chemoresistant type of ovarian cancer, 
and conventional chemotherapy is not regarded as an 
effective treatment. In this review, we focus on potential 
therapeutic molecular targets and discuss prospective 
treatments.
Review
Molecular mechanisms of platinum resistance in ovarian 
CCC
Several mechanisms involved in platinum resistance have 
been proposed, including pre-, on-, post-, and off-target 
mechanisms as well as the speed of cell proliferation 
[14]. Our consideration of platinum resistance in CCC is 
shown in Fig. 1 and summarized in Table 1 [15–53].
Pre-target mechanisms include at least two mecha-
nisms using which cancer cells elude the cytotoxic poten-
tial of cisplatin before binding to cytoplasmic targets 
and DNA: (1) a reduced intracellular accumulation of 
cisplatin and (2) an increased sequestration of cisplatin 
by glutathione, metallothioneins, and other cytoplasmic 
scavengers with nucleophilic properties [14].
Previous studies have shown that the expression of 
the ABCC3 gene is significantly greater in CCC than in 
SAC. Increased expression of ABCC3 may, at least in 
part, be associated with the chemoresistant phenotype of 
CCC [19]. Moreover, AnxA4 overexpression reportedly 
stimulates efflux of platinum drugs and induces plati-
num resistance [20, 54, 55]. Increased sequestration of 
platinum agents in CCC has also been reported, with 
significantly increased glutathione concentrations in cell 
lines after cisplatin exposure [56]. Furthermore, a study 
of gene expression showed that glutathione peroxidase 
3, glutaredoxin, and superoxide dismutase 2 were highly 
expressed in CCC tumors and that elevated levels of 
these proteins may render the tumors more resistant to 
chemotherapy [57].
The on-target mechanism involves repair of adducts 
at an increased pace and/or the ability to tolerate unre-
paired DNA lesions, reflecting activity of a particular 
class of DNA polymerases [14]. The majority of cisplatin 
lesions are removed from DNA by the nucleotide exci-
sion repair (NER) system [14, 58]. One study revealed 
higher mRNA expression of ERCC1 and XPB genes in 
CCC. These genes are involved in the NER pathway of 
EOC and are more prevalent in CCC than in other histo-
logical subtypes of EOC [35]. This phenomenon may be 
related to de novo drug resistance against chemothera-
peutic agents in CCC.
Post-target resistance to cisplatin may follow several 
alterations, including defects in signal transduction path-
ways and issues with cell death machinery [14]. In this 
mechanism, galectin-3 is associated with CCC platinum 
resistance, and suppression of galectin-3 reportedly leads 
to cis-diamminedichloroplatinum-induced apoptosis via 
decreases in p27 protein expression [42].
Regarding the off-target mechanism, accumulating evi-
dence suggests that the cisplatin-resistant phenotype can 
also be maintained by alterations in signaling pathways 
that are not directly engaged by cisplatin, and yet, these 
compensate for cisplatin-induced lethal signals [14]. Epi-
dermal growth factor receptor (EGFR) and human epi-
dermal growth factor receptor 2 (HER2) are cell-surface 
receptor tyrosine kinases that are capable of activating 
both mitogen-activated protein kinase and phosphati-
dylinositol 3-kinase (PI3K)/AKT signaling pathways. This 
leads to phosphorylation of BAD and Bcl-2 and results in 
the inhibition of chemotherapy-induced apoptosis. An 
immunohistochemical study reported that the expres-
sion of EGFR was detected in 61 % of CCC tumors [46]. 
Furthermore, HER2 was reportedly overexpressed in 
CCC in comparison with other major histological sub-
types of EOC. In ovarian cancer, the HER2 protein was 
overexpressed as a consequence of gene amplification 
in 20–25  % of cases and predicted poor prognosis [59, 
60]. Moreover, HER2 was overexpressed in 42.9  % of 
CCC cases, as investigated using immunohistochemistry 
(IHC) [61].
Slow cell proliferation is also associated with plati-
num resistance because cytotoxic drugs primarily target 
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proliferating cells [5], and doubling times for CCC cells 
were significantly longer than those for SAC cells (61.4 
vs. 29.8 h) [5].
Determining the mechanisms underlying platinum 
resistance in CCC is important, because no novel drugs 
have yet proven effective for CCC treatment. Our review 
revealed that annexin A4 (AnxA4) is one of the most 
well-investigated platinum resistance factors in CCC [20, 
22–25]. A recent study showed that AnxA4 knockout 
improved platinum resistance of CCC in vitro and in vivo 
[56], and the functional site of AnxA4 that is responsible 
for conferring platinum resistance has been identified. If 
an AnxA4 blockade drug was developed, its use in com-
bination with platinum drugs could have therapeutic 
activity against CCC.
Characteristics of ovarian CCC
The molecular features of CCC are summarized in Table 2 
[22, 24, 46, 52, 53, 61–72]. One major distinguishing char-
acteristic is its higher incidence among Asian populations, 
particularly among Japanese women [2, 3, 56]. The reason 
for this is unknown, although CCC has been associated 
with endometriosis and endometriosis-associated ovarian 
cancers in 22–70 % of younger female patients [73]. Previ-
ous studies showed that ovarian endometrioma increases 
the risk for ovarian cancer, and 0.72 % of all cases of ovar-
ian endometrioma later develop neoplasms [74].
CCC tends to present at significantly earlier stages 
than other ovarian cancers, possibly owing to slow tumor 
growth and frequent presentation of tumors as large pel-
vic masses [75], and the proportion of stage I/II tumors 
ranges from 59 to 71 % [3].
Unlike high-grade serous EOCs, CCCs usually display 
a wild-type p53 and have a lower frequency of BRCA1 
and BRCA2 mutations [2, 76, 77]. Significant differences 
were reported in the distribution of mutations among 
histological subtypes, and TP53 mutations were report-
edly present in 67 and 21 % of cases with serous and non-
serous cancers, respectively [76]. Similar studies report 
much lower frequencies of p53 mutations (approximately 
15  %) in CCC than in other EOC types [2]. Similarly, 
Alsop et  al. reported that the frequency of BRCA1 and 
BRCA2 mutations of CCC was 6.3 and 0 %, respectively 
[77]. However, other recent studies have revealed that 
several genes/proteins are mutated and/or overexpressed 
in CCC, and that these proteins may serve as therapeutic 
targets for CCC (Table 2) [22, 24, 46, 52, 53, 61–72].
Novel therapeutic modalities for CCC
Paclitaxel plus carboplatin combination therapy is cur-
rently the primary treatment strategy in postoperative 
chemotherapy. However, advanced-stage patients even-
tually relapse after adjuvant therapy and have a high 
risk of recurrence [3, 5, 6]. The mechanism underlying 
resistance to standard chemotherapy has been studied 
but remains unknown. Nonetheless, novel drugs that 
target specific molecular pathways are being developed 
to improve the outcomes of chemotherapy-resistant 
Fig. 1 Mechanisms of platinum resistance in CCC. At present, five mechanisms of platinum resistance have been characterized in CCC, including 
pre‑, on‑, post‑, and off‑target mechanisms, and slow cell proliferation. ABCC3 ATP‑binding cassette, subfamily C, member 3, ERCC1 excision repair 
cross‑complementing rodent repair deficiency complementation group 1, EGFR epidermal growth factor receptor, HER2 human epidermal growth 
factor receptor 2
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Table 1 Summary of potential targets for platinum resistance in CCC
Category of platinum resistance Target molecule
 Pre target
ABCC3
Function ABCC3 is expressed in the liver, small intestine, and colon. ABCC3 belongs to the ABCC subfamily, consisting of 13 
members in mammals that are divided into three classes: multi‑drug resistance proteins, sulfonylurea receptors, 
and the cystic fibrosis transmembrane conductance regulator [15]. ABCC3 transports monovalent bile salts (i.e., 
taurocholate and glycocholate) and sulfated bile salts(i.e., taurochenodeoxycholate‑3‑sulfate, taurolithocholate‑
3‑sulfate) [15]
In cancer tissues Overexpression of ABCC3, which transports chemotherapeutic agents, has been associated with paclitaxel resist‑
ance in breast cancer cell lines [16, 17] and cisplatin resistance in ovarian cancer cell lines [18]
In CCC One study reported that ABCC3 mRNA expression in CCC was significantly higher than that in SAC [19]. However, 
no study to date has investigated potential mechanisms of platinum resistance in CCC
Annexin A4
Function Annexin A4 (Anx A4) is a member of the Ca2+‑regulated and phospholipid‑binding annexin protein superfamily, 
and is believed to be involved in exocytosis and regulation of epithelial Cl− secretion [20]
In cancer tissues Studies indicate that Anx A4 up‑regulation promotes tumor progression and chemoresistance in colorectal cancer, 
esophageal squamous cell carcinoma, endometrial carcinoma, gastric cancer, chemoresistant lung cancer, 
malignant mesothelioma, renal cell carcinoma, ovarian clear cell carcinoma (CCC), cholangiocarcinoma, hepato‑
cellular carcinoma, breast cancer, and laryngeal cancer [21]
In CCC Enhanced Anx A4 expression was identified in both clinical samples and ovarian CCC cell lines by 2‑D differential 
gel electrophoresis (2D‑DIGE) and mass spectrometry [22]. Anx A4 confers chemoresistance to ovarian CCC cell 
lines [23]. Proposed mechanisms of annexin‑A4‑mediated chemoresistance include (1) reduction of intracellular 
platinum content and (2) enhancement of NF‑kB transcriptional activity via interaction of Anx A4 with NF‑kB. 
Anx A4 is one of the most investigated platinum resistance factors in CCC [20, 22–25]
Glutathione peroxidase 3 (GPx3)
Function The Glutathione Peroxidase (GPx) family is composed of eight members (GPx1–GPx8) that play roles in removing 
redundant reactive oxygen species (ROS) to reduce oxidative damage to host cells. The GPx3 gene is located on 
chromosome 5q23 and encodes a protein that accounts for nearly all GPx activities in plasma [26]
In cancer tissues GPx3 expression has been reported in hepatocellular carcinoma, gastric cancer, acute myeloid leukemia, and clear 
cell renal cell carcinoma [27]. One study reported a correlation between GPx3 methylation and chemoresistance 
in head and neck cancer (HNC), which may serve as a potential prognostic indicator of HNC after cisplatin‑based 
chemotherapy [28]
In CCC Only one study to date has investigated the role of GPx3 in CCC [29]. The GPx3 gene was found to be highly 
expressed in CCC by DNA microarray analysis. GPx3 suppression by RNA interference increased cisplatin sensitiv‑
ity by approximately 4‑fold in CCC cell lines. Since GPx3 suppression increased cisplatin sensitivity of CCC cells, 
GPx3 may be a candidate gene associated with platinum resistance in CCC [29]
 On target
ERCC1 (NER system)
Function ERCC1 was the first human DNA repair gene identified by molecular cloning. The ERCC1 and ERCC4 genes encode 
the two subunits of ERCC1‑XPF nuclease, an enzyme that plays an important role in DNA repair and main‑
tenance of genomic stability [30]. ERCC1‑XPF nuclease nicks DNA specifically at junctions between double‑
stranded and single‑stranded DNA, when the single‑strand is oriented in a 5′ to 3′ direction away from a junc‑
tion. ERCC1‑XPF is a core component of nucleotide excision repair and plays a role in interstrand crosslink repair, 
some pathways of double‑strand break repair by homologous recombination and end‑joining, as a backup 
enzyme in base excision repair, and in telomere length regulation [30]
In cancer tissues ERCC1 is perhaps one of the most important components of the NER pathway and a key determinant of cisplatin 
resistance. When we consider the role that it plays in other DNA repair processes, such as recombination, it 
is observed that in recent years, ERCC1 has become one of the most studied prognostic factors of platinum 
therapy [31]. ERCC1 is reportedly a platinum‑resistance factor in cancers of the ovary, lung, colorectum, and 
stomach [31–34]
In CCC Although a detailed investigation was not conducted, one study detected higher ERCC1 mRNA levels in CCC 
specimens than other histological types of epithelial ovarian cancer [35]. Because ERCC1 was found to play an 
important role in platinum resistance in other cancers, further investigations into the role of ERCC1 in CCC are 
expected
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ovarian cancer. Moreover, studies of chemotherapy-
resistant ovarian cancer therapy indicate that effective 
treatments for CCC are available. However, clinical data 
relating directly to the treatment of CCC subtypes are 
limited.
Clinical trials have shown that in combination with 
chemotherapy, targeting vascular endothelial growth fac-
tor (VEGF), VEGF receptor (VEGFR), mammalian target 
of rapamycin (mTOR), EGFR, and poly (ADP-ribose) pol-
ymerase elicits positive results for EOC (Table 3) [52, 61, 
ABCC3 ATP-binding cassette, subfamily C, member 3, ABC ATP-binding cassette, CCC clear cell carcinoma, SAC serous adenocarcinoma, GPx glutathione peroxidase, 
ERCC1 excision repair cross-complementing rodent repair deficiency complementation group 1, NER nucleotide excision repair, EGFR epidermal growth factor 
receptor, HER2 human epidermal growth factor receptor 2. We summarized the factors of platinum resistance in CCC. We introduced the factors of normal function, 
function in cancer, and function in CCC
Table 1 continued
Category of platinum resistance Target molecule
 Post target
Galectin 3
Function: The galectins comprise a family of 14 members of β‑galactoside‑binding proteins, which are characterized by an 
affinity for β‑galactosides and a conserved sequence in the carbohydrate recognition domain that binds to the 
carbohydrate portion of cell surface glycoproteins or glycolipids [36]. Galectin 3 is widely expressed in epithelial 
and immune cells in the gastric mucosa, colon mucosa, mammary epithelium, and prostate epithelium, as well 
as monocytes and macrophages. The Galectin 3 gene encodes a 31‑kDa multifunctional oncogenic protein that 
plays a role in the regulation of cell growth, adhesion, proliferation, and apoptosis, as well as angiogenesis [36]
In cancer tissues Galectin 3 has been implicated in many aspects of cancer progression, such as tumor cell adhesion, proliferation, 
differentiation, and metastasis [37], and is associated with platinum resistance in cancers of the ovary, pancreas, 
and prostate [38–41]. Galectin 3 has also been shown to protect cells against chemotherapy‑induced apoptosis 
and has been implicated in the regulation of universal apoptosis commitment [37]
In CCC Only one study to date has investigated the role of Galectin 3 in CCC [42]. Cisplatin‑induced apoptosis was 
increased after Galectin 3 knock‑down. Immunohistochemical staining showed that Galectin 3 expression in 
CCC was significantly more frequent than in SAC. Because p27 protein expression was decreased after Galectin 3 
knock‑down, the author concluded that Galectin 3 expression in CCC might contribute to decreased cell prolif‑
eration and lead to cisplatin resistance [42]
 Off target
EGFR
Function Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein that belongs to the receptor tyrosine 
kinase family of growth factor receptors and participates in important physiological process, such as cell survival, 
proliferation, and motility [43]
In cancer tissues EGFR overexpression has been associated with advanced disease and poor survival of patients with cancers of 
the breast, lung, liver, prostate, and ovary [43]. Alterations to EGFR coding sequences are also frequently found 
in human cancers. Most variants with deletions in the extracellular domain are correlated with poor survival. In 
general these variants are constitutively active and confer a growth advantage and increased malignant poten‑
tial to tumor cells [43, 44]. Overexpression or mutated EGFR is reportedly associated with platinum resistance in 
lung and ovarian cancer [14, 43, 45]
In CCC A previous study reported EGFR overexpression in approximately 60 % CCC specimens and selective inhibition of 
the EGFR decreased growth and invasion of ovarian CCC cells [46]. Another study reported that EGFR inhibition 
increased cisplatin efficacy in ovarian CCC cells [47]. Together, the results of these studies suggest that EGFR is an 
important therapeutic target to improve platinum‑resistance in CCC
HER2
Function HER2 (ErbB2) is a type I transmembrane protein that belongs to the EGFR family, which includes EGFR, ErbB1, 
HER1, HER3, and −4 (ErbB3 and −4) [48]. Normal HER2 function is associated with cellular differentiation, 
growth, development, and apoptosis via activation of tyrosine kinase activity through dimerization of HER2, with 
itself or other members of the EGFR family [48]
In cancer tissues Amplification or overexpression of HER2 occurs in approximately 15–30 % of breast cancers and 10–30 % of 
gastric/gastroesophageal cancers, and serves as a prognostic and predictive biomarker. HER2 overexpression has 
also been identified in cancers of the ovary, endometrium, bladder, lung, colon, and head/neck. The introduction 
of HER2‑directed therapies has dramatically influenced the outcome of patients with HER2‑positive breast and 
gastric/gastroesophageal cancers; however, the results have proved disappointing in other HER2‑overexpressing 
cancers [49]. The association between HER2 and platinum resistance in breast cancer cells [50] and the data 
of a systematic review suggest that triple‑negative breast cancer have increased sensitivity to platinum‑based 
chemotherapy [51]
In CCC Amplification and overexpression of HER2 have been described in 14–42.9 % of Ovarian CCC cases [52, 53]. How‑
ever, no report to date has investigated the association between HER2 and mechanisms of platinum resistance 
in CCC
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71, 78–83]. However, limited data are available pertaining 
to novel therapies for either EOC or CCC, and further 
studies of novel treatment strategies are required to focus 
on the clinical features of CCC.
Targeting VEGF
VEGF is an important therapeutic target in several solid 
tumors, including ovarian cancers, and the monoclo-
nal antibody bevacizumab has been shown to bind to 
VEGF, inhibit receptor binding, and prevent the growth 
of tumor vasculature. Accordingly, the International Col-
laborative Ovarian Neoplasm Group (ICON7) and the 
Gynecologic Oncology Group (GOG) trials (GOG218) 
of bevacizumab addition to standard chemotherapy in 
newly diagnosed advanced ovarian cancer both reported 
significant improvements in PFS. The ICON7 trial spe-
cifically reported increased OS in a predefined group of 
patients with a high risk of disease progression [84, 85]. 
In addition, efficacy and safety of bevacizumab has been 
reported both in patients with platinum-sensitive and in 
those with platinum-resistant recurrent ovarian cancers 
[84, 85]. However, in these studies, histological subgroup 
analyses were not performed, and the clinical utility of 
VEGF as a therapeutic target for CCC has not been eval-
uated. Mabuchi et al. demonstrated the efficacy of bevaci-
zumab in in vitro and in vivo CCC models, which showed 
that VEGF is frequently expressed and may be a promis-
ing therapeutic target for the management of CCC [66]. 
However, a clinical trial has not been performed. Suni-
tinib is another possible therapeutic option for renal cell 
carcinoma treatment and acts as an oral, small-molecule, 
multitargeted receptor tyrosine kinase inhibitor (target-
ing VEGFR, platelet-derived growth factor receptor, and 
c-Kit). However, only a few small clinical studies have 
reported the efficacy of sunitinib for ovarian CCC [86].
Targeting the PI3K/AKT/mTOR signaling pathway
PI3Ks are lipid kinases that regulate signaling path-
ways that are vital for neoplasia, including cell prolif-
eration, adhesion, survival, and motility. The frequency 
of PIK3CA mutations in CCC has been estimated to 
be 40  %, and some studies suggest that the PI3K/AKT/
mTOR pathway is a target with therapeutic potential [53]. 
Moreover, immunohistochemical analyses have shown 
that mTOR is frequently activated in CCC (86.6 %) and 
that mTOR inhibition by RAD001 may be an effective 
treatment for CCC [63]. Furthermore, Rahman et  al. 
reported that PIK3CA mutations were associated with 
more favorable prognoses but did not predict the sensi-
tivity of ovarian CCC cells to PI3K/AKT/mTOR inhibi-
tors [87]. Since more than 80  % of ovarian CCC shows 
activation of the AKT/mTOR pathway, it is of great inter-
est to explore the potential of mTOR inhibitors [88]. 
A very important GOG clinical trial is currently being 
conducted. The GOG-268 trial is an open-label phase II 
trial for newly diagnosed stage III and IV ovarian CCC 
to examine the activity of one of the mTOR inhibitors, 
temsirolimus. The primary endpoint of this trial is PFS 
at 12 months, and secondary endpoints include adverse 
events, duration of PFS and OS, and tumor response. 
Table 2 Characteristics of ovarian clear cell carcinomas and potential molecular targets
ARID1A AT-rich interactive domain 1A (SWI-like) gene, BRCA 1/2 breast cancer susceptibility gene 1/2, EGFR epidermal growth factor receptor, HER2 human epidermal 
growth factor receptor 2, HNF-1β hepatocyte nuclear factor 1β, mTOR mammalian target of rapamycin, PIK3CA phosphoinositide 3-kinase catalytic-α, PPMID protein 
phosphatase magnesium-dependent, PP2R1A protein phosphatase 2, regulatory subunit A, VEGF vascular endothelial growth factor, ZNF217 zinc finger protein 217
Clinical features Mutated genes and overexpressed proteins Reference
Higher incidence among Asian women, particularly Japanese 
women
ARID1A is mutated in 46 % of CCC patients (loss of function) [62, 85]
Clear cell carcinoma has a strong association with endometriosis PIK3CA is mutated in 33 % of CCC patients (activation mutation) [53]
Slow tumor growth, facilitating early detection Annexin A4 is expressed in almost all CCC patients [20, 22]
Strong resistance to platinum‑based chemotherapy mTOR is overexpressed in 80 % of CCC patients [63]
Promising regimens with favorable and stable response for ovarian 
clear cell carcinoma have remained elusive
HNF‑1β is expressed in almost all CCC patients [52, 64, 71–73]
Low frequency of BRCA1/2 mutations ZNF217 is overexpressed in 20 % of CCC patients [65]
Low frequency of p53 mutations (15 %) VEGF is strongly expressed in both early and advanced stages of 
CCC
[66]
EGFR is overexpressed in 60 % of CCC patients [59]
MET is overexpressed in approximately 20 % of CCC patients [85]
HER2 is overexpressed in 14–42.9 % of CCC patients [52, 53]
PPMID expression is observed in 10 % of CCC patients [68]
PPP2R1A is overexpressed in 7 % of CCC patients [52]
KRAS is overexpressed in 5 % of CCC patients [52]
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Table 3 Examples of targeted molecular cancer therapeutics for epithelial ovarian cancer
Category Target molecule Agent(s) References
Angiogenesis Vascular endothelial growth factor Bevacizumab [71, 85]
Function Bevacizumab is a humanized recombinant monoclonal antibody that inhibits vascular 
endothelial growth factor (VEGF) receptor binding
Efficacy A clinical trial of bevacizumab addition to standard chemotherapy treatment in 
newly diagnosed advanced ovarian cancer demonstrated its efficacy. Bevacizumab 
monotherapy is effective in the treatment of persistent, resistant, or recurrent epi‑
thelial ovarian cancer (EOC). However, it remains unknown whether bevacizumab is 
effective for the clinical treatment of clear cell carcinoma (CCC). Some reports have 
suggested its efficacy in vitro and in vivo
Vascular endothelial growth factor receptor Sorafenib [71]
Function Sorafenib is a multikinase inhibitor of intracellular Raf kinases and cell surface kinase 
receptors and thereby inhibits tumor growth and angiogenesis
Efficacy Phase I and II studies show limited clincial benefits of sorafenib in the treatment of 
EOC, both as monotherapy and in combination with other drugs. No data is avail‑
able regarding its use in the treatment of clear cell carcinoma (CCC). However, it is 
regarded as a useful therapy for patients with renal CCC. Therefore, sorafenib may be 
efficacious in the treatment of CCC
Vascular endothelial growth factor receptor Pazopanib [71]
Function Pazopanib is a tyrosine kinase (multikinase) inhibitor that limits angiogensis and tumor 
growth by inhibiting cell surface vascular endothelial growth factor receptors (VEG‑
FRs), platelet‑derived growth factor receptors, and fibroblast growth factor receptors
Efficacy Pazopanib monotherapy was relatively well tolerated, with similar toxicity to that of 
other small‑molecule oral angiogenesis inhibitors. Promising single‑agent activity 
was demonstrated in patients with recurrent ovarian cancer. Phase II and III trials 
indicate that pazopanib may have a role in the treatment of some women with EOC. 
No data demonstrates its efficacy in the treatment of CCC. However, pazopanib is 
regarded as useful in the treatment of renal CCC patients
Growth factor Epidermal growth factor receptor Gefitinib, erlotinib, and lapatinib [78]
Function Gefitinib is a tyrosine kinase inhibitor that inhibits numerous tyrosine kinases that are 
associated with transmembrane cell surface receptors on both normal and cancer 
cells, including the epidermal growth factor receptor (EGFR) assoicated tyrosine 
kinase
Efficacy EGFR‑targeted treatment had no effect when administered as monotherapy or as an 
adjunct to chemotherapy. However, EGFR‑targeted treatment has shown promise in 
combination with other chemotherapeutic agents in clinical use. Further reports are 
expected. No data show the effects of targeting EGFR in CCC patients
Human epidermal growth factor receptor 2 Trastuzumab [79]
Function Trastuzumab is a monoclonal antibody that binds to the extracellular domain of the 
human epidermal growth factor receptor 2 protein (HER 2) and mediates antibody‑
dependent cellular cytotoxicity by inhibiting the proliferation of cells that overex‑
press the HER 2 protein
Efficacy HER‑2 gene and protein overexpression have been reported in breast cancer and are 
associated with an aggressive clinical course and poor prognosis. A Gynecologic 
Oncology Group study demonstrated that HER 2 overexpression has no predictive 
or prognostic value in ovarian cancer. Although trastuzumab is not useful for ovarian 
cancer, no studies have investigated its use in the treatment of ovarian CCC. Further 
studies are needed to determine the efficacy of trastuzumab in the treatment of 
ovarian CCC
Insulin-like growth factor type I receptor AMG479 [80]
Function A complete human monoclonal antibody against insulin‑like growth factor type I 
receptor (IGF‑1R)
Efficacy IGF‑1R inhibition with ganitumab was well tolerated and demonstrated modest 
single‑agent activity in unselected patients with platinum‑sensitive recurrent ovarian 
cancer. To our knowledge, two clinical trails have been completed, although the 
results have nto yet been published. There are no data pertaining to its use in the 
treatment of CCC
Tumor Marker Cancer antigen 125 Oregovomab [71]
Function Oregovomab is a monoclonal antibody that binds to the antigen cancer antigen (CA 
125)
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IHC expression of components of the mTOR signaling 
pathway will be explored. Temsirolimus will be adminis-
tered in combination with paclitaxel and carboplatin for 
six cycles. For the maintenance phase, temsirolimus will 
be administered on days 1, 8, and 15 every 3 weeks for 11 
cycles. This clinical trial closed, and clinicians are await-
ing the results with high expectations. Although targeting 
the PI3K/AKT/mTOR signaling pathway is promising, 
some problems remain, and there is no evidence of effec-
tive clinical management of CCCs, warranting further 
studies and clinical trials to prove the efficacy of PI3K/
AKT/mTOR inhibition.
Targeting AnxA4
AnxA4 is reportedly involved in exocytosis and regu-
lation of epithelial Cl− secretion [20], and its overex-
pression in CCC has been shown to induce platinum 
resistance [22]. Accordingly, IHC analyses of AnxA4 in 
CCC samples showed strong staining in 30 of 43 samples 
but moderate staining in the remaining 13 samples [22].
Table 3 continued
Category Target molecule Agent(s) References
Efficacy A phase III clinical trial of intravenous oregovomab as post‑chemotherapy consoli‑
dation has been conducted for EOC of tubal or peritoneal origin. Oregovomab 
monotherapy failed to improve outcomes after first line therapy. There are no data 
pertaining to its use in the treatment of CCC
Adhesion α5β1 integrin Volociximab [81]
Function Volociximab binds to and inhibits the activity of α5β1 integrin
Efficacy A phase II, multicenter, single arm, two stage study evaluated the efficacy, safety, and 
tolerability of weekly administration of volociximab as a single agent for the treat‑
ment of platinum‑resistant, advanced EOC and primary peritoneal cancer. Volocixi‑
mab was well tolerated, but there is insufficient evidence of its efficacy. There are no 
reports of volociximab treatments for CCC
Signal Mammalian target of rapamycin Temsirolimus [82]
Function The mammalian target of rapamycin (mTOR) signaling pathway senses and integrates 
a variety of environmental cues to regulate growth and homeostasis. Temsirolimus is 
an inhibitor of the mTOR pathway
Efficacy Inhibitors of mTOR have shown therapeutic advantages when used in combination 
with other therapeutic modalities. Although clinical activity was low compared with 
the expected benefits, warranting further investigation. Existing data demonstrates 
the efficacy of targeting the mTOR pathway for CCC treatment in vitro and in vivo
Src Dasatinib [71]
Function Elevated activity of Src tyrosine kinase is suggested to be linked to cancer progression 
through the promotion of other signals. Dasatinib is a BCR‑ABL tyrosine kinase inhibi‑
tor. It also inhibits the Src family, c‑KIT, EPHA2, and platelet‑derived growth factor 
receptor β
Efficacy Dasatinib has minimal activity as a single agent in patients with recurrent EOC. There 
are no data pertaining to its use in the treatment of CCC
c-Kit Imatinib [71]
Function c‑Kit is a receptor tyrosine kinase type III, which binds to stem cell factor, also known 
as “steel factor” or “c‑kit ligand”. Signaling through c‑kit plays a role in cell survival, 
proliferation, and differentiation
Efficacy Some reports show dissapointing results in clinical outcomes. Few patients had 
sustained responses or stable disease, and treatment with imatinib did not prolong 
progression‑free survival
DNA repair Poly ADP ribose polymerase Iniparib [83]
Function Proteins of the poly ADP ribose polymerase (PARP) family are involved in several cellular 
processes, mainly involving DNA repair and programmed cell death. Iniparib was 
originally believed to act as an irreversible inhibitor of PARP1
Efficacy Phase II multicenter, single‑arm clinical studies have been conducted to assess the effi‑
cacy and safety of carboplatin/gemcitabine in combination with iniparib in patients 
with platinum‑sensitive or ‑resistant recurrent ovarian cancer. Phase III clinical trial of 
olaparib was initiated for patients with BRCA mutant ovarian cancer. However, low 
frequency of BRCA1/2 mutations in CCC were reported
ABL Abelson murine leukemia, BCR breakpoint cluster region, CA125 cancer antigen 125, EGFR epidermal growth factor receptor, EPHA2 ephrin type-A receptor 2, GFR 
growth factor receptor, HER2 human epidermal growth factor receptor 2, IGF-1R insulin like growth factor-1 receptor, mTOR mammalian target of rapamycin, PARP poly 
(ADP-ribose) polymerase, PDGFR platelet-derived growth factor receptor, VEGF vascular endothelial growth factor, VEGFR vascular endothelial growth factor receptor
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Nonetheless, enhanced AnxA4 expression was recently 
shown to increase chemoresistance to carboplatin by con-
tributing to extracellular efflux of the drug [22]. Recently, 
we demonstrated molecular mechanisms underlying 
AnxA4-induced promotion of platinum drug efflux [54]. 
Exposure of an AnxA4-overexpressing endometrial car-
cinoma cell line to platinum drugs caused relocalization 
of AnxA4 from the cytoplasm to the membrane fraction, 
and colocalization of P-type ATPase ATP7A (a copper 
and platinum transporter) to cell membranes. This colo-
calization promoted platinum drug efflux via ATP7A and 
induced the platinum resistance [54].
Several studies have shown that AnxA4 induces drug 
resistance [20], and suppression of AnxA4 expression 
improved platinum sensitivity of CCC in vitro and in vivo 
[55]. In addition, Morimoto et  al. showed that annexin 
repeat domains and calcium-binding sites of repeated 
annexin sequences are required for resistance to plati-
num-based drugs [55]. The structure of AnxA4 and the 
mechanism of platinum resistance induced by AnxA4 is 
shown in Fig. 2. Taken together, these reports suggest the 
potential of AnxA4 targets for the treatment of ovarian 
CCC. However, no drugs have been shown to suppress 
AnxA4 expression. Nonetheless, in a study of the related 
annexin A2 (AnxA2) using chick chorioallantoic mem-
brane assays, neutralizing antibodies significantly inhib-
ited OV-90 cell motility and invasion in vitro and in vivo, 
suggesting the potential of AnxA2-neutralizing antibod-
ies as therapeutic targets for AnxA2-overexpressing can-
cers [89]. Similarly, AnxA4 blockade using neutralizing 
antibodies might limit the platinum resistance of CCC 
and is currently under investigation by our research 
group. Potentially, drugs that inhibit the function of 
AnxA4 in combination with platinum drugs may offer 
promising therapies for the treatment of CCC.
Targeting the ARID1A gene
The AT-rich interactive domain 1A (SWI-like) gene 
(ARID1A) encodes BAF250A, which is a member of the 
SWI/SNF ATP-dependent chromatin remodeling com-
plex. ARID1A plays an indispensable role in controlling 
gene expression and in tissue development and cellular 
differentiation [70]. Moreover, CCCs reportedly have the 
highest frequency of ARID1A mutations (43–57 %) [62].
Yamamoto et  al. reported two critical associations 
between the AT-rich interactive domain-containing pro-
tein 1A (ARID1A) and CCC. In particular, deficiencies of 
ARID1A immunoreactions were evident at the stage of 
precursor lesions that lacked atypical cytology, indicat-
ing that the loss of ARID1A protein may occur as an early 
event in tumorigenesis. Moreover, loss of ARID1A pro-
tein expression is often coincident (not mutually exclu-
sive) with PIK3CA mutation [90]. However, a previous 
study demonstrated that inactivation of ARID1A alone 
is insufficient for tumor initiation, suggesting that addi-
tional genetic alterations are required to drive tumorigen-
esis [91]. Chandler et al. also showed that the coexistent 
ARID1A-PIK3CA mutations promote ovarian clear cell 
tumorigenesis [92]. Taken together, these studies suggest 
that ARID1A is related to CCC tumorigenesis, although 
Fig. 2 The structure of annexin A4 (AnxA4) and related mechanisms of platinum resistance. a No treatment. AnxA4 is localized in the cytoplasm 
before exposure to platinum drugs. b After platinum drug exposure. Exposure to platinum drugs leads to AnxA4 relocalization from the cytoplasm 
to the cell membrane. AnxA4 has four annexin repeats that are packed into an α‑helical disk within the C‑terminal polypeptide core, which contains 
Ca2+‑binding sites. These Ca2+‑binding sites are involved in platinum resistance. c After platinum drug exposure. AnxA4 is attached to the mem‑
brane surface through bound Ca2+ ions and contributes to the efflux of platinum drugs via platinum transporters
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the precise mechanisms remain unknown, and no drugs 
have yet been shown to target ARID1A. A recent study 
by Bitler et al. is an important study regarding the target-
ing of ARID1A for ovarian CCC [93]. The study showed 
that ARID1A is mutated in over 50  % of ovarian CCCs 
and pharmacological inhibition of enhancer of zeste 
homolog 2 (EZH2) represents a novel treatment strat-
egy for cancers involving ARID1A mutations. The study 
showed that EZH2 inhibitor selectively suppressed the 
growth of ARID1A mutated cells in vitro and in vivo via 
upregulating the expression of PIK3IP1, which negatively 
regulates PI3K/AKT signals. Further studies are expected 
to elucidate the detailed mechanisms of the cellular dys-
function caused by ARID1A mutations in CCCs and to 
expose the potential of ARID1A as a therapeutic target.
Targeting hepatocyte nuclear factor‑1β
Hepatocyte nuclear factor-1β (HNF-1β) is a transcrip-
tion activator that regulates the promoters and enhancers 
of genes expressed in the liver, digestive tract, pancreas, 
and kidneys [64]. Recent studies have reported specific 
expression of HNF-1β in endometriosis and CCC and 
suggest that early differentiation into the clear cell line-
age occurs in endometriosis [64, 74]. However, the role 
of HNF-1β expression in ovarian clear cell tumors and 
endometriosis remains uncertain. Nonetheless, RNA 
interference has been used to decrease HNF-1β expres-
sion and reportedly led to apoptotic cell death in CCC 
cell lines, indicating that HNF-1β expression may be 
tightly linked to CCC and that it could be essential for its 
survival [74]. In addition, HNF-1β is reportedly expressed 
in almost all CCC cases [64].
Accordingly, Kajihara et  al. concluded that the HNF-
1β-dependent pathway may provide novel insights into 
the regulation of glycogen synthesis, detoxification, and 
resistance to anticancer agents [94]. In support of these 
conclusions, HNF-1β directly regulates multiple cancer-
related genes, including those for dipeptidyl peptidase IV, 
osteopontin, tissue factor pathway inhibitor 2, AnxA4, 
and angiotensin-converting enzyme 2 [74, 94, 95]. Genes 
that are upregulated in CCC are likely direct targets of 
HNF-1β. However, drugs that target HNF-1β have not 
been developed, warranting further studies of the mecha-
nisms by which HNF-1β regulates various genes and its 
association with CCC.
Targeting ZNF217
The ZNF217 gene on human 20q13.2 encodes a tran-
scription factor that is overexpressed in 30  % of breast 
tumors and in several cell lines [96]. Several studies 
show that overexpression of ZNF217 in several cancers 
is associated with poor prognosis [96, 97]. Among these, 
Littlepage et  al. reported that ZNF217 overexpression 
promotes metastasis and resistance to chemotherapy and 
inhibits signaling events in vivo [96]. These authors also 
showed that triciribine inhibits the growth of ZNF217-
overexpressing cells in vitro and in vivo, indicating that it 
is a potential target for the treatment of ZNF217-overex-
pressing cancers.
In a previous study, ZNF217 overexpression was 
reported in 20.0 % of CCC cases [65]. Moreover, Rahman 
et al. showed that ZNF217 gene overexpression is signifi-
cantly correlated with lymph node metastasis in ovarian 
CCC. In comparison with small interfering RNA-treated 
cells without ZNF217 overexpression, profound inhibi-
tion of cell migration and invasion was observed in cells 
overexpressing ZNF217 [98], suggesting that ZNF217 is a 
potential therapeutic target for CCC.
Conclusion
As discussed above, the loss of ARID1A expression and/
or PI3K activation is crucial for CCC tumorigenesis. 
Moreover, synergic effects of the loss of ARID1A expres-
sion and PI3K/AKT pathway activation and ZNF217 
overexpression may be related to ovarian CCC develop-
ment [99], warranting further studies of these associa-
tions and assessments of their potential as co-therapeutic 
targets for CCC.
CCC is highly resistant to current platinum-based 
treatment. However, if an AnxA4 blockade drug was 
developed, its use in combination with platinum drugs 
may have therapeutic activity against CCC.
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